Transformative Research in Diabetic Nephropathy
TRIDENT is a unique public-private initiative that aims to develop ground-breaking diabetic kidney disease therapeutics.
In patients with diabetes, having diabetic-related kidney disease (or diabetic nephropathy) strongly correlates with increased risk of death. Despite improvements in medical care, the risk of progressing to end-stage kidney failure requiring dialysis or kidney transplant remains increased in diabetic patients.
TRIDENT aims to partner with patients who have diabetes and kidney disease. We believe that investigating this relationship will enable us to understand the disease mechanisms that result in diabetic nephropathy, and thus, to develop potential therapeutics to prevent diabetic kidney disease progression and kidney failure.
Comprehensive clinical phenotyping will be complemented with in-depth molecular analysis to identify targetable mechanisms that 1) underlie the development of diabetic nephropathy and 2) result in the deterioration of kidney function. Our studies will incorporate non-invasive discovery efforts to identify biomarkers associated with disease progression and treatment response. This all-inclusive, multifaceted approach will enable us to advance and implement precision medicine-derived therapeutic approaches for patients living with diabetic kidney disease.
2018 Steering Committee Meeting - October 9 – Philadelphia, PA
© The Trustees of the University of Pennsylvania | Site best viewed in a supported browser. | Report Accessibility Issues and Get Help | Site Design: PMACS Web Team.